Use of anti-fam19a5 antibodies for treating atherosclerosis
AssigneeNeuracle Science Co., Ltd.
InventorsBongcheol KIM, Dong Sik KIM, Jae-Keun LEE, Juwon SHIM
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.
Claims53
An antagonist against a family with sequence similarity 19, member A5 (“FAM19A5”) protein (“FAM19A5 antagonist”) for increasing a phagocytosis of low density lipoprotein (LDL) by macrophages in a subject in need thereof.
An antagonist against a family with sequence similarity 19, member A5 (“FAM19A5”) protein (“FAM19A5 antagonist”) for increasing a migration and/or accumulation of macrophages at an atherosclerotic lesion site in a subject in need thereof.
An antagonist against a family with sequence similarity 19, member A5 (“FAM19A5”) protein (“FAM19A5 antagonist”) for reducing a low density lipoprotein (LDL) level in a subject in need thereof.
An antagonist against a family with sequence similarity 19, member A5 (“FAM19A5”) protein (“FAM19A5 antagonist”) for treating an atherosclerosis in a subject in need thereof.
Dependencies are inferred from the claim text.